| July 18, 2023 |
Timely Disclosure Information
|
StemRIM Announces Patent Registration (Korea) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction
|
| June 14, 2023 |
Financial Results
|
[Delayed]Non-consolidated Financial Results for the Nine Months Ended April 30, 2023[Japanese GAAP]
|
| June 1, 2023 |
IR News
|
StemRIM Announces Exhibiting at the “BIO International Convention 2023” and Participating in the “Jefferies 2023 Global Healthcare Conference New York”
|
| May 24, 2023 |
Timely Disclosure Information
|
StemRIM Announces Orphan Drug Designation of Regeneration-Inducing Medicine Redasemtide (HMGB1 peptide)
|
| May 22, 2023 |
Timely Disclosure Information
|
StemRIM Announces Results from Phase 2 Clinical Trial of Redasemtide in Patients with Chronic Liver Disease (Additional Report)
|
| May 18, 2023 |
Timely Disclosure Information
|
[Delayed]StemRIM Announces Patent Registration (Taiwan) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction
|
| May 16, 2023 |
IR News
|
StemRIM Announces Publication of Scientific Articles for Stem Cell Gene Therapy (PJ5)
|
| April 28, 2023 |
Timely Disclosure Information
|
StemRIM Announces Milestone Achievement in Development of Therapeutic Drug (Redasemtide) Targeting Acute Ischemic Stroke
|
| April 11, 2023 |
Timely Disclosure Information
|
[Delayed] StemRIM Announces Preliminary Results from Phase 2 Clinical Trial of Redasemtide in Patients with Chronic Liver Disease
|
| April 11, 2023 |
Timely Disclosure Information
|
[Delayed] Notice of Earnings Forecasts for the Fiscal Year Ending July 31, 2023
|
| April 11, 2023 |
Timely Disclosure Information
|
[Delayed] StemRIM Announces Milestone Achievement in Development of Therapeutic Drug (Redasemtide) Targeting Acute Ischemic Stroke
|
| March 16, 2023 |
Financial Results
|
[Delayed]Non-consolidated Financial Results for the Six Months Ended January 31, 2023[JapaneseGAAP]
|
| December 14, 2022 |
Financial Results
|
[Delayed]Non-consolidated Financial Results for the Three Months Ended October 31, 2022[JapaneseGAAP]
|
| September 8, 2022 |
Financial Results
|
[Delayed]Non-consolidated Financial Results for the Fiscal Year Ended July 31, 2022[Japanese GAAP]
|
| June 9, 2022 |
Financial Results
|
[Delayed]Non-consolidated Financial Results for the Nine Months Ended April 30, 2022[Japanese GAAP]
|
